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Geﬁtinib is an oral, reversible, tyrosine kinase inhibitor of epidermal growth factor receptor (EGFR) that plays a key role in the
biology of non small cell lung cancer (NSCLC). Phase I studies indicated that the recommended dose of geﬁtinib was 250mg/day.
Rash, diarrhea, and nausea were the most common adverse events. The positive results obtained in early phase 2 clinical trials
with geﬁtinib were not conﬁrmed in large phase 3 trials in unselected patients with advanced NSCLC. The subsequent discovery
that the presence of somatic mutations in the kinase domain of EGFR strongly correlates with increased responsiveness to EGFR
tyrosine kinase inhibitors prompted phase 2 and 3 trials with geﬁtinib in the ﬁrst line-treatment of EGFR-mutated NSCLC. The
results of these trials have demonstrated the eﬃcacy of geﬁtinib that can be now considered as the standard ﬁrst-line treatment of
patients with advanced NSCLC harbouring activating EGFR mutations.
1.Introduction
Geﬁtinib (ZD1839, Iressa) is an orally administered, rever-
sible tyrosine kinase inhibitor (TKIs) of epidermal growth
factor receptor(EGFR),belonging to the smallmolecule class
(quinazoline-derivative molecule) [1]. The EGFR family
includes four diﬀerent tyrosine kinase receptors: EGFR
(ErbB-1), ErbB-2, ErbB-3, and ErbB-4 [2]. Each of these
proteins has an extracellular ligand-binding domain, a single
hydrophobic transmembrane domain and a cytoplasmic
tyrosine kinase-containing domain. The receptors of the
ErbB family are activated following binding to peptide
growth factors of the EGF-family. Upon ligand binding, the
ErbB receptors form either homo- or heterodimers and,
following dimerization, auto- and transphosphorylation in
tyrosine residues of the ErbB receptors occurs [3]. EGFR
signaling plays a key role in promoting the growth and
survival ofvarioustypesofsolidtumors,includingnonsmall
cell lung cancer (NSCLC) [4, 5].
Geﬁtinib has an inhibitory eﬀect both on the autophos-
phorylationanddownstream signaling, competingreversibly
with the adenosine triphosphate (ATP) for the catalytic
domain of EGFR. In vitro studies indicated that geﬁtinib
potently inhibited EGFR tyrosine kinase activity at low
concentrations that did not signiﬁcantly aﬀect other kinases
tested [6]. In vivo studies showed that geﬁtinib had a
favourable tolerability proﬁle and an antitumor activity
in various xenograft models and enhanced the antitumor
activity of a variety of cytotoxic drugs, including platinum
compounds [7, 8]. Geﬁtinib was well tolerated in healthy
volunteers and showed a terminal half-life of 28 hours,
supporting the once-daily oral administration [9].2 Journal of Biomedicine and Biotechnology
This paper focuses on the clinical development of
geﬁtinib in NSCLC, discussing the causes of its failure in
unselected NSCLC patients and summarizing the available
evidence coming from the randomized phase 3 trials that
support the use of geﬁtinib as the standard ﬁrst line
treatment of patients with advanced NSCLC harbouring
EGFR mutations.
2.Phase IClinicalStudies
Geﬁtinib has been evaluated as single agent in four phase
1 clinical trials, including patients with advanced refractory
solid tumors. In the ﬁrst study, conducted in UK and USA,
geﬁtinib was administered once daily for 14 consecutive
days, followed by 14 days oﬀ treatment [10]. Dose escalation
started at 50mg and continued to 925mg or until consis-
tent dose-limiting toxicity (DLT). Sixty-four patients were
entered at eight dose levels. The most frequent dose-related
grade 1 and 2 adverse events were acne-like rash, nausea, and
diarrhea. Three of9patientstreatedat700mg/daydeveloped
DLT (reversible grade 3 diarrhea). Four of 16 patients
with NSCLC had partial responses (observed from 300 to
700mg/day). In the second study, including 88 patients in
Europe and Australia, geﬁtinib was administered at dose
ranging from 150 to 1000mg/day in28-day cyclesto patients
with either advanced non small cell lung, ovarian, head and
neck, prostate, or colorectal cancer [11]. At 1000mg/day,
5 of 12 patients experienced DLT (grade 3 diarrhea in
four patients and grade 3 somnolence in one patient). The
most frequent adverse events were acne-like rash (64%) and
diarrhea (47%), which were generally mild (grade 1/2) and
reversible on cessation of treatment. Nineteen patients had
stable disease and received geﬁtinib for >3 months. In the
third study, conducted in USA, 71 patients were enrolled at
seven dose levels (ranging from 150 to 1000mg/day in 28-
day cycles) and most had NSCLC (n = 39) [12]. Diarrhea
and rash, the primary DLTs, occurred at 800mg. Frequent
treatment-related grade 1-2 adverse events were diarrhea
(55%), asthenia (44%), and acne-like follicular rash (46%).
At doses >800mg, 45% of patients required dose reductions.
One partial response and 6 prolonged stable disease were
observed in patients with NSCLC. The fourth phase 1
study investigated the tolerability and toxicity of geﬁtinib in
Japanese patientswithsolidtumors[13].Thirty-one patients
were included and received oral geﬁtinib on 14 consecutive
days, every 28 days. Dose escalation was from 50mg/day to a
maximum of 925mg/day or DLT. The most frequent adverse
eventswerean acne-likerash andgastrointestinal sideeﬀects.
Two of 6 patients at 700mg/day had DLT; no further dose
escalation occurred. A partial response was observed in 5 of
the 23 patients with NSCLC (duration 35–361 days) over a
rangeofdoses(225–700mg/day),and7patientswithvarious
tumors had disease stabilization. Therefore, geﬁtinib showed
afavourabletolerabilityproﬁleand antitumoractivity also in
Japanese patients. Moreover, pharmacokinetic analyses from
all these studies conﬁrmed the feasibility of the once daily
schedule.
The preclinical evidence of synergism between geﬁtinib
and chemotherapy provided the rationale for a feasibility
study designed to assess the tolerability and antitumor
activity of the combination of two doses of geﬁtinib (250
and 500mg/day), gemcitabine and cisplatin (at standard
doses) in chemotherapy-na¨ ıve patients with advanced or
metastatic solid tumors, and to assess whether there was
a pharmacokinetic interaction between these drugs when
administered concurrently [14]. Eighteen patients were
entered,9at eachgeﬁtinib doselevel.Two patientsdeveloped
DLT: one grade 3 convulsion (250mg/day dose group)
and one grade 3 rash (500mg/day dose group). The most
commongrade3/4adverseeventswerevomiting(7patients),
asthenia (6 patients), thrombocytopenia (6 patients), diar-
rhea (5patients),and anorexia (5patients).Pharmacokinetic
analyses showed no apparent pharmacokinetic interaction
between geﬁtinib and cisplatin or gemcitabine, with the
exception of a possible small increase in the geometric mean
exposure to gemcitabine seen on day 8 of therapy when
given alone with the higher dose of geﬁtinib. Of 10 evaluable
patients with NSCLC, 5 had conﬁrmed partial response, 4
had stable disease and 1 had progressive disease.
3.Development ofGeﬁtinibin
“Unselected” Patients
3.1. Phase II Clinical Studies. Two randomized phase 2
clinical studies evaluated the safety and the activity of two
dosesofgeﬁtinib(250mg or500mg)assecond- orthird-line
therapy of NSCLCpatients (IDEAL1 and IDEAL2) [15, 16].
The IDEAL-1 (Iressa Dose Evaluation in Advanced Lung
cancer) study recruited 210 patients who were pretreated
with one or two chemotherapy regimens, at least one
containing platinum [15]. The IDEAL-2 study included 221
patients who were pretreated with two or more regimens
containing platinum and docetaxel [16]. In both studies,
the two doses of geﬁtinib produced similar results in terms
of objective responses (approximately 20% in IDEAL-1
and 10% in IDEAL-2), disease control rate (about 50% in
IDEAL 1 and 40% in IDEAL2), and overall survival (about 8
months in IDEAL 1 and 7 months in IDEAL 2). Overall, the
incidence of toxic eﬀects, including skin rash and diarrhea,
was lower in patients treated with 250mg/day as compared
with patients treated with 500mg/day. These results led to
choosing the lower dose for subsequent development of the
drug in NSCLC. In both trials, an attempt has been made to
identify predictive factors for objective response to geﬁtinib.
In the IDEAL-1 study, a multivariate analysis showed that
performance status, previous immuno/hormonal treatment,
histology, and female gender were signiﬁcantly associated
with a higher response rate, while in the IDEAL-2 study
only female gender was signiﬁcantly predictive of response
to geﬁtinib. The promising results of these trials led, in
2003, the Food and Drug Administration (FDA) to grant
an accelerated approval for geﬁtinib as monotherapy
treatment for patients with locally advanced or metastatic
NSCLC after failure of both platinum-based and docetaxel
chemotherapies.
The results of other phase 2 studies conducted with
geﬁtinib as single agent in unselected patients with advanced
NSCLC are summarized in Table 1 [15–23].Journal of Biomedicine and Biotechnology 3
Table 1: Phase II clinical trials with Geﬁtinib as single agent in “unselected” NSCLC.
Author (yr) Setting Design Pts Geﬁtinib dose Results Toxicity
Fukuoka et al.
(2003) [15]
Pretreated with
1-2 lines
Randomized
phase 2 210 250mg versus
500mg
RR: 18.4% (250mg) versus
19% (500mg); PFS: 2.7
versus 2.8 months
Diarrhea, rash and other
skin events
Kris et al. (2003)
[16]
Pretreated with
2-3 lines
Randomized
phase 2 221 250mg versus
500mg
RR: 12 versus 9%; OS: 7
versus 6 months
Diarrhea, rash and other
skin events
D’Addario et al.
(2008) [17] Chemonaive Phase 2,
single arm 63 250mg RR: 9.5 %; DSR at 12
weeks: 38%
Rash and other skin
events, hepatotoxicity
Wan et al.
(2006) [18]
Not ﬁt for
chemo or
pretreated
Phase 2,
single arm 151 250mg RR: 29.8%; TTP: 12
months;1yr OS: 57%
Rash, diarrhea,
nasal/oralmucosa
bleeding
Lin et al. (2006)
[19] Chemonaive Phase 2,
single arm 53 250mg
RR: 32.1%; TTP: 12
months;OS: 15.3 months;
1yr OS: 57%
Skin toxicity, diarrhea,
nail change, ILD
Niho et al.
(2006) [20] Chemonaive Phase 2,
single arm 42 250mg RR: 30%; OS: 13.9 months;
1yr OS: 55%
Rash and other skin
events, ILD
Reck et al.
(2006) [21] Chemonaive Phase 2,
single arm 58 250mg R R :5 % ;T T P :1 . 8m o n t h s ;
OS: 7.3 months
Skin toxicity and
diarrhea
Suzuki et al.
(2006) [22] Chemonaive Phase 2,
single arm 34 250mg RR: 26.5%; OS: 14 months;
1yr OS: 58.2%
Rash, fatigue,
hepatotoxicity
Spigel et al.
(2005) [23] Chemonaive Phase 2,
single arm 70 250mg
R R :4 % ;T T P :3 . 7m o n t h s ;
OS: 6.3 months;1yr OS:
24%
Rash and diarrhea
RR: response rate; PFS: progression-free survival; OS: overall survival; DSR: disease stabilizationrate; TTP: time to progression; ILD: interstitiallung disease.
3.2. Phase III Clinical Studies in First-Line Therapy. The
encouraging results obtained in early clinical trials and
the preclinical evidence of synergism between geﬁtinib and
chemotherapy prompted two large randomized phase 3
clinical trials examining the role of geﬁtinib in combination
with standard chemotherapy (cisplatin plus gemcitabine in
INTACT-1 and carboplatin plus paclitaxel in INTACT-2)
for the ﬁrst line treatment of advanced NSCLC [24, 25].
Both of these studies failed to demonstrate any advantage
in overall survival for patients treated with chemotherapy
in combination with geﬁtinib. Moreover, subgroups analyses
of predictive factors of sensitivity to geﬁtinib did not
demonstrate any survival advantage for speciﬁc subgroups
when geﬁtinib was added to chemotherapy. Negative results
were similarly observed with the combination of another
tyrosine kinase inhibitor, erlotinib, with chemotherapy
(TALENT and TRIBUTE studies) [26, 27]. Several explana-
tionsregarding thelackofanadditiveeﬀectbetweentyrosine
kinase inhibitors and chemotherapy have been proposed:
a mechanistic interaction between geﬁtinib or erlotinib
and chemotherapy, for which the antiproliferative eﬀects
of anti-EGFR agents may render tumor cells less sensitive
to cytotoxic agents, as suggested by preclinical studies; the
possibility that patients who beneﬁt from EGFR-targeted
treatmentsarethesamewholikelyrespondtochemotherapy:
in this case, the eﬀect of tyrosine kinase inhibitors can be
masked by the eﬀect of chemotherapy; ﬁnally, the lack of
patient selection based on the expression of EGFR [28].
Because no additive eﬀect was observed by administer-
ing geﬁtinib in combination with chemotherapy, a phase 3
t r i a lw a sc o n d u c t e dt oe v a l u a t et h ee ﬃcacy of a sequential
strategy, with geﬁtinib given after ﬁrst line platinum-
doublet chemotherapy for NSCLC, which might have
avoided problems of drug interference or antagonism [29].
Unfortunately, sequential geﬁtinib therapy after three cycles
of standard platinum doublet chemotherapy showed no
survival beneﬁt over platinum doublet chemotherapy up to
six cycles (HR 0.86, 95%CI 0.72–1.03, P = .11), although
sequential geﬁtinib was associated with signiﬁcantly pro-
longedprogression-free survival (HR0.68,95%CI0.57–0.80;
P<. 001). An exploratory subset analysis demonstrated
a possible survival prolongation for sequential therapy of
geﬁtinib,forpatientswithadenocarcinoma(HR0.79,95%CI
0.65–0.98, P = .03).
Table 2 summarizes theresults oftherandomized clinical
trials with geﬁtinib in ﬁrst- and second-line therapy, in
locally advanced disease and adjuvant setting and in special
populations [24, 25, 29–38].
3.3. PhaseIII Clinical Studies in Second-Line Therapy. Am ul-
ticenter phase 3 study compared geﬁtinib as monotherapy
at the dose of 250mg/day to placebo in 1692 pretreated
patients with NSCLC [30]. Patients treated with geﬁtinib
reported signiﬁcantly higher response rate (8% versus 1.3%)
and longer time to treatment failure (3.0 versus 2.6 months).
However, treatment with geﬁtinib was not associated with
signiﬁcant improvementin survival intheoverallpopulation
(5.6 versus 5.1 months in the geﬁtinib and placebo arms,
resp.) nor in the subgroup of patients with adenocarcinoma.
There was pronounced heterogeneity in survival outcomes
between groups of patients, with some evidence of beneﬁt
among never-smokers (median survival of 8.9 versus 6.14 Journal of Biomedicine and Biotechnology
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months; HR 0.67; 95% CI 0.49–0.92, P = .012) and
Asian ethnicity (9.5 versus 5.5 months; HR 0.66; 95%CI
0.48–0.91, P = .01). Explanations of the negative results
of this trial could be the large number of chemotherapy
refractory patients (90%), a suboptimal dose of geﬁtinib and
the lack of selection based on potential molecular markers,
associated with clinical outcome. In addition, exploratory
biomarker analyses, including the assessment of EGFR gene
copy number by FISH, EGFR and p-AKT protein expression
byIHC,EGFR,K-RASandD-RAFmutationalstatus,showed
a trend towards a better survival outcome for geﬁtinib in
patients with high EGFR-gene-copy number (HR 0.61 for
high copy number and HR 1.16 for low copy number,
P = .045), while patients with EGFR mutations obtained
higher RR than wild-type patients (37.5% versus 2.6%)
[31]. No relationship was observed between p-AKT protein
expression and survival outcome. On the basis of the lack of
survival beneﬁt in the ISEL study, in 2005 the FDA restricted
the use of geﬁtinib to patients continuing to beneﬁt from
treatment already initiated or participating in clinical trials.
Four randomized trials compared geﬁtinib versus doc-
etaxel as a second-line therapy of advanced NSCLC patients.
An open-label randomized phase 2 study (SIGN trial—
Second line Indication of Geﬁtinib in NSCLC) compared
geﬁtinib (250mg/day) with docetaxel (75mg/mq every 3
weeks) in 135 patients with advanced pretreated NSCLC
[32]. Primary objective of this trial was symptom improve-
ment using the FACT-L questionnaire. Geﬁtinib and doc-
etaxel showed similar activity (symptom improvement rates
of 36% and 26%, response rate of 13.2% and 13.7%, median
progression-free survival of 3 and 3.4 months, median
overall survival of 7.5 and 7.1 months, with quality of life
improvement rates of 33.8% and 26% for geﬁtinib and
docetaxel, resp.). However, geﬁtinib had a more favorable
tolerability proﬁle than docetaxel (adverse events of all
grades: 51.5% versus 78.9%; grade 3-4: 8.8% versus 25.4%).
The INTEREST trial was the largest study comparing
geﬁtinib todocetaxelassecond- orthird-line therapy in 1466
patients with advanced NSCLC treated with prior platinum-
based chemotherapy [33]. The coprimary endpoints were
the noninferiority of geﬁtinib in comparison with docetaxel
in terms of overall survival in the total population and
the superiority in patients expressing a high EGFR gene
copy number. The study demonstrated the noninferiority of
geﬁtinib (OS 7.6 versus 8.0 months, with a 1-year survival of
32% versus 34%, in the geﬁtinib and docetaxel arms, resp.,
HR 1.02, 96% CI 0.905–1.150, meeting the pre-deﬁned non
inferiority criterion of 1.154), while failed to demonstrate
the superiority of geﬁtinib in the subgroup of 174 patients
with high EGFR gene copy number: in this setting, median
survival was 8.4 months in the geﬁtinib group and 7.5
months in the docetaxel group, and 1-year survival was 32
and 35%, respectively (HR 1.09; 95% CI 0.78–1.151, P =
.620). The most common adverse events in the geﬁtinib
group were skin reactions (49% versus 10%) and diarrhea
(35% versus 25%), whereas in docetaxel group neutropenia
(5% versus 74%), asthenia (25% versus 47%), and alopecia
(3% versus 36%). Signiﬁcantly more patients had sustained
clinically relevant improvement in quality of life with
geﬁtinib than with docetaxel, as assessed by FACT-L total
score (OR 1.99,95% CI 1.42–2.79;P<. 0001)and the FACT-
L-TOI (OR 1.82, 95%CI 1.23–2.69; P = .0026). Similar
proportions of patients had improvements in lung cancer
symptoms (FACT-L LCS) with geﬁtinib and docetaxel (OR
1.29, 95%CI 0.93–1.79; P = .013). Moreover, a biomarkers
analysis was conducted in this trial on 453 patients (31%)
who had tissue samples evaluable for at least one biomarker
(EGFR copy number by ﬂuorescent in situ hybridization,
EGFR protein expression by immunohistochemistry, and
EGFR and KRAS mutations) and showed no diﬀerence in
overall survival between treatments for any biomarker [34].
However, notably, among patients with EGFR mutation-
positive tumors, PFS was longer (HR 0.16; 95% CI 0.05–
0.49, P = .001) and objective response was higher (42.1%
versus 9.8%) for geﬁtinib as compared to docetaxel. Overall
survival was longer in patients with EGFR mutation-positive
tumors in both geﬁtinib and docetaxel subgroups (median
survival 14.2 and 16.6 months, resp.) than in the overall
population(7.6and 8.0 months, resp.) and in thepopulation
with wild-type EGFR (6.4 and 6.0 months, resp.), but there
was no diﬀerence between treatments. Finally, exploratory
analyses showed no diﬀerence between patients with high
and low EGFR copy number within the geﬁtinib arm (high
versus low HR, 1.02, 95% CI 0.74–1.41, P = .914) and no
signiﬁcant diﬀerencesin survival outcomebetween the study
arms according to KRAS mutation status.
Two further randomized phase 3 clinical trials (con-
ducted in Japan and Korea, resp.) compared geﬁtinib versus
docetaxel in patients with locally advanced or metastatic
NSCLC, pretreated with one or two chemotherapy regimens
[35, 36]. The Japanese trial did not meet the primary
objective (non inferiority of geﬁtinib versus docetaxel) in
terms of overall survival (11.5 months for geﬁtinib versus
14 months for docetaxel), although fewer severe adverse
events (40.6% versus 81.6%) and beneﬁts in terms of quality
of life improvement occurred with geﬁtinib compared with
docetaxel [35]. In the Korean study, geﬁtinib improved
signiﬁcantly objective response rate (28.1 versus 7.6%) and
PFS (HR 0.73, 90%CI 0.53–0.98, P = .0441) than docetaxel
[36]. However, no diﬀerences were observed in terms of
OS (14.1 versus 12.2 months in the geﬁtinib and docetaxel
arms, resp.) and quality of life or symptom improvement
rates. A meta-analysis of the randomized clinical trials
comparing geﬁtinib to docetaxel was presented at 2009
ASCO Meeting and showed similar overall and progression-
free survival between the two drugs and superior response
rate with geﬁtinib [37]. Therefore, given the similar eﬃcacy
demonstrated by geﬁtinib, its favorable tolerability proﬁle,
the quality of life beneﬁts, and the oral administration, the
Authors concluded that geﬁtinib has a favorable beneﬁt-
risk proﬁle compared with docetaxel in a broad pretreated
advanced NSCLC patient population.
3.4. Phase III Clinical Studies in Adjuvant and Locally
Advanced Setting. A single phase 3 trial of adjuvant geﬁtinib
has been conducted to date (the BR.19 trial), starting in
the early 2000s, when a great enthusiasm existed for explor-
ing the potential of this drug in NSCLC treatment [38].6 Journal of Biomedicine and Biotechnology
In the BR.19 trial, patients with completely resected stage
IB to IIIA NSCLC were randomly assigned to receive daily
geﬁtinib 250mg or placebo, for two years. They could also
receive adjuvant chemotherapy as appropriate. The primary
end-point was overall survival. The study planned to enrol
1160 patients, but it was stopped prematurely in 2005,
following the negative results of the ISEL study [30]a n d
the SWOG S0023 trials [39] .A tt h et i m eo fs t u d yc l o s u r e ,
503 patients had been enrolled. Data were presented at
2010 ASCO Annual Meeting. Median age of patients was
67; 54% were male, 54% PS 0 and most of them were
ever smoker (89%); most of tumors were adenocarcinoma
(59%); only 17% of patients received chemotherapy. Median
followup was 4.7 years. Median time on treatment was 4.8
months in both arms. Diﬀerences were not signiﬁcant for
both overall survival (HR 1.24; 95% CI 0.94–1.64; P =
.14) and disease-free survival (HR 1.22, 95% CI 0.93–1.61;
P = .15), with a negative trend for geﬁtinib treatment.
The toxicity analysis excluded the possibility of attributing
this disadvantage to a higher incidence of fatal toxicity in
the geﬁtinib arm. Preplanned subgroup analyses according
to EGFR mutational status (357 evaluable patients, 76 of
whom with mutation) demonstrated no beneﬁt for geﬁtinib
treatment in both wild-type and mutant NSCLC patients,
with a more evident negative trend just in patients with
EGFR mutations (HR 1.58, 95% CI 0.83–3.00; P = .16).
Although all the comparisons have weak power due to the
small number of the patients, these results are very striking
and preclude the use of adjuvant geﬁtinib outside from
clinical trials.
The above-mentioned SWOG S0023 trial [39]c o m p a r e d
maintenance geﬁtinib to placebo after concurrent chemora-
diotherapy and docetaxel consolidation in inoperable stage
IIIA and IIIB NSCLC patients. Overall survival was the
primary end-point. This study also closed prematurely, on
the recommendation of an unplanned interim analysis that
was prompted by the results of the ISEL trial. Of the
571 eligible patients registered at the time of the interim
analysis (against the 840 planned), 234 were randomized to
receive geﬁtinib 500mg or placebo, daily for ﬁve years. The
interim analysis of this study showed that the hypothesized
alternative of a 33% improvement in survival with geﬁtinib
over placebo was ruled out with a one-sided P = .0015.
Updated results, after a median followup of 27 months,
were successively published, showing that patients receiving
geﬁtinib had a worse survival than patients on placebo, with
a median survival of 23 compared with 35 months (HR 0.63,
95% CI 0.44–0.91; P = .013). As in the BR.19 trial, the
analysis of cancer-related and toxic death revealed that the
inferior survival was due to tumor progression and not to
geﬁtinib toxicity. Unfortunately, molecular features of the
tumors, including EGFR mutations, were not recorded in
this study. The detrimental eﬀect of maintenance geﬁtinib
afteroptimalcytoreductionwithchemoradiotherapyinstage
III NSCLC reported by the S0023trial excludesthe use of the
drug in this setting of disease.
The evidence coming from these two randomized trials
do not support the use of geﬁtinib in the localized stages
of NSCLC patients, even with tumors carrying EGFR
mutations. The intrathoracic disease could have a diﬀerent
biologic behavior that should be further explored.
3.5. Randomized Clinical Studies in Special Populations. In
consideration of its good toxicity proﬁle, geﬁtinib has been
tested as an alternative to a single-agent chemotherapy in
elderly and poor performance status (PS) NCSLC patients.
A randomized phase II trial was conducted by Crin` oe t
al. with geﬁtinib (250mg daily) versus vinorelbine in 196
untreated elderly (≥70 years) NSCLC patients [40]. The
trial was designed to determine the superiority of geﬁtinib
versus vinorelbine in terms of progression-free survival.
The results showed no statistical diﬀerence in progression-
free survival (2.7 versus 2.9 months, HR 1.19, 95%CI,
0.85–1.65, P = .310), overall survival (5.9 versus 8.0
months; HR0.98, 95%CI, 0.66–1.47),and response rate (3.1
versus 5.1%) between geﬁtinib and vinorelbine, respectively.
However, geﬁtinib showed a better toxicity proﬁle. Most of
the enrolled patients were male (77%), smokers (82%), and
with squamous cell carcinoma, thus without clinical features
conferring sensitivity to geﬁtinib, and this may explain the
low percentage of responders in this study.
Goss et al. compared geﬁtinib to BSC in 201 untreated
NCSLC patients with PS ≥ 2, not eligible for chemotherapy,
in a randomized phase II trial [41]. Primary endpoint
was PFS and, nevertheless the results showed no statistical
diﬀerence, there was a trend toward improved progression-
free survival (HR 0.82, 95%CI, 0.60–1.12, P = .217), overall
survival (HR 0.84, 95% CI, 0.62–1.15, P = .272) and
response rate (6% versus 1 % placebo) in favor of geﬁtinib.
4.Development ofGeﬁtinibin
“Selected” Patients
4.1. Phase II Clinical Studies. The recent discovery that some
somatic mutations in the tyrosine kinase domain of the
EGFR gene are associated with a high response to EGFR
tyrosine kinase inhibitors in NSCLChighlighted the need for
patient selection through molecular screening [42, 43].
Several phase 2 studies showed a high response rate
(55–90%) and a prolonged progression-free survival (of
approximately 9 months) with ﬁrst-line geﬁtinib in Asiatic
patients selected on the basis of the presence of activating
EGFR gene mutations [44–56]. The results of these studies
are summarized in Table 3. Yang and colleagues observed
in 43 patients with exon 19 deletions and L858R mutations
a response rate of 95% and 73.9% and a progression-
free survival of 8.9 and 9.1 months, respectively [46].
The iTARGET trial selected chemo-na¨ ıve patients with
nonsquamous histology who had one or more clinical
characteristics associated with activating EGFR mutations,
such as low or never smoking history, adenocarcinoma
histology, female gender, and East Asian ethnicity [47]. In
this study, mutations were identiﬁed in 35% of patients and
31 patients received geﬁtinib: the response rate was 55%,
the median progression-free survival was 9.2 months, and
overall survival was 17.5 months. Actually, the response rate
was 78% and 59% for patients carrying L858R mutation
and exon 19 deletion, respectively, which are activatingJournal of Biomedicine and Biotechnology 7
Table 3: Phase II trials with Geﬁtinib as single agent in “selected” patients with NSCLC.
Author (yr) Setting Pts Treatment Results Toxicity
Asahina et al. (2006)
[44]
Chemonaive, EGFR
mutation 16 Geﬁtinib 250mg RR: 75%; PFS: 8.9 months,
1yr OS: 88% Rash, hepatotoxicity
Inoue et al. (2006)
[45]
Chemonaive, EGFR
mutation 16 Geﬁtinib 250mg RR: 75%; PFS: 9.7 months;
1yr OS: 88% Skin toxicity, stomatitis, diarrhea
Yang et al. (2008) [46]Chemonaive, EGFR
mutation 55 Geﬁtinib 250mg RR: 84.2%; PFS: 8.9
months, OS: 24 months
Skin toxicity, hepatotoxicity,
diarrhea
Sequist et al. (2008)
[47]
Chemonaive, EGFR
mutation 31 Geﬁtinib 250mg RR: 55%; PFS: 9.2 months,
OS: 17.5 months
Skin toxicity, diarrhea, nausea,
fatigue
Sutani et al. (2006)
[48]
1st-2nd line, EGFR
mutation 27 Geﬁtinib 250mg RR: 78%; PFS: 9.4 months,
OS: 15.4 months Diarrhea, skin toxicity
Yoshida et al. (2007)
[49]
Chemonaive, EGFR
mutation 21 Geﬁtinib 250mg RR: 90%; TTP: 7.7 months Skin toxicity, diarrhea,
hepatotoxicity
Sunaga et al. (2007)
[50]
Chemonaive, EGFR
mutation 19 Geﬁtinib 250mg RR: 76%; DSR: 90%; TTP:
12.9 months Skin toxicity
Tamura et al. (2008)
[51]
Chemonaive, EGFR
mutation 27 Geﬁtinib 250mg RR: 75%; DSR: 96%; PFS:
11.5 months,1yr OS: 79%
Skin toxicity, hepatotoxicity,
stomatitis,diarrhea
Sugio et al. (2009)
[52]
Chemonaive, EGFR
mutation 19 Geﬁtinib 250mg RR: 63.2%; PFS 7.1
months, OS: 20 months Skin toxicity, nail change
Inoue et al. (2009)
[53]
Chemonaive, EGFR
mutationand poor PS 30 Geﬁtinib 250mg
RR: 66%, DSR 90%, PFS
6.5 months,OS 17.8
months, PS improvement
rate: 79%
Hepatotoxicity, anemia, skin
toxicity
Cappuzzo et al.
(2007) [54]
FISH positive or
never smokers 42 Geﬁtinib 250mg RR: 47.6%; PFS: 6.4
months; 1y OS: 64%. Skin toxicity, diarrhea
West et al. (2006) [55]
Brochoalveolar
carcinoma, 1st-2nd
line
91 Geﬁtinib 500mg
RR: 9% and OS 13 months
in 2nd line; RR 17% and
OS 13 months in 1st line
Skin toxicity, diarrhea
D. H. Lee et al. (2005)
[56]
Adenocarcinoma and
never smokers 37 Geﬁtinib 250mg RR: 69%; PFS: 33 weeks;
1yr OS: 73% Skin toxicity, diarrhea
RR: response rate; PFS: progression-free survival; OS: overall survival; DSR: disease stabilizationrate; TTP: time to progression.
mutations, predictive for response to geﬁtinib, whereas it
was 0% in patients with atypical mutations. Therefore, this
study has demonstrated that genotype-directed EGFR-TKI
therapy with geﬁtinib for patients with previously untreated
NSCLC is feasible also in a Western population. Inoue et
al. tested geﬁtinib in a phase II trial in NSCLC patients
harbouring EGFR mutations and with poor PS, not eligible
for chemotherapy [53] .T on o t e ,2 2o f3 0p a t i e n t sh a dv e r y
poor PS (3 or 4). The overall response rate was 66%, with
disease stabilization rate of 90%. PS improvement rate was
79%. The median progression-free and overall survival were
6.5 and 17.8 months, respectively. This is the ﬁrst report
indicating that EGFR mutation-positive patients with poor
PS can beneﬁt from front line geﬁtinib treatment. Others
phase II trials have selected patients on the basis of clinical,
pathological, or molecular features. The ONCOBELL trial
enrolled 42 patients who were never smokers or who had
evidence of a high EGFR gene copy on FISH and were p-
AKT positive [54]. The response rate was 47.6%, the median
time to progression was 6.4%, and 1-year survival rate was
64.3%.In EGFR-mutated patients(66.8%),the response rate
was 62.5%. The Southwest Oncology Group performed a
phase II trial for pretreated (n = 22) or untreated (n = 69)
patients with bronchioalveolar carcinoma [55] .T h ed o s eo f
geﬁtinib used in this trial was 500mg/day. The response rate
in the pretreated and untreated patients was 9% and 17%,
respectively. Finally, a phase II trial investigated the activity
of geﬁtinib 250mg daily in 37 chemo-na¨ ıve Korean patients
with adenocarcinoma and a never-smoking history [56].The
response rate was 69% with a disease stabilization rate of
81%; median progression-free survival and 1-year survival
rate were 33 weeks and 73%, respectively.
4.2. Phase III Clinical Studies. Four randomized phase III
clinical trials evaluated the role of geﬁtinib as ﬁrst line
therapy of patients with advanced NSCLC, selected on
the basis of clinical or molecular features (Table 4)[ 57–
60]. The ﬁrst evidence of eﬃcacy of a therapeutic strategy
based on an EGFR tyrosine kinase inhibitor as a ﬁrst-line
treatment of patients with advanced NSCLC derived from a
large, randomized phase 3 clinical trial conducted in Asian
patients, the IPASS study [57]. The IPASS (IRESSA Pan
Asia Study) trial randomized 1217 patients with advanced
adenocarcinoma, non-smoker or former light smoker, to
receive geﬁtinib, 250mg daily until progression or unac-
ceptable toxicity, or carboplatin (AUC 5-6) plus paclitaxel
(200mg/m2) for a maximum of 6 cycles. The study met
the primary objective (non inferiority of geﬁtinib) and8 Journal of Biomedicine and Biotechnology
Table 4: Phase III trials with Geﬁtinib in “selected” NSCLC.
Author (yr) Study Setting Pts Treatment RR (%) PFS (mos) OS (mos)
Mok et al.
(2009) [57] IPASS
1st line,
clinically
selected
1217
Geﬁtinib versus
Carboplatin +
Paclitaxel
43 versus 32.3
(P = .0001)
5.7 versus 5.8
HR: 0.74, 95%
CI: 0.65–0.85,
P<. 0001
18.6 versus 17.3
HR: 0.91,
95%CI:
0.76–1.10
Subgroup of
EGFR mutated 261
71.2 versus
47.3
(P<. 001)
9.5 versus 6.3
HR: 0.48, 95%
CI: 0.36–0.64,
P<. 001
HR: 0.78, 95%
CI 0.50–1.20
J. S. Lee et al.
(2009) [58]
FIRST
SIGNAL
1st line,
clinically
selected
309
Geﬁtinib versus
Cisplatin +
Gemcitabine
53.5 versus
45.3
(P = .153)
6.1 versus 6.6
HR: 0.813, 95%
CI: 0.641–1.031,
P = .044
21.3 versus 23.3
HR: 1.003,
95%CI:
0.749–1.343,
P = .428
Subgroup of
EGFR mutated 42
84.6 versus
37.5
(P = .002)
8.5 versus 6.7
HR: 0.613, 95%
CI: 0.308–1.221,
P = .084
30.6 versus 26.5
HR: 0.823, 95%
CI: 0.352–1.922,
P = .648
Mitsudomi et
al. (2010)
[59]
WJTOG
3405
1st line, EGFR
mutated 172
Geﬁtinib versus
Cisplatin +
Docetaxel
62.1 versus
32.2
(P<. 0001)
9.2 versus 6.3
HR 0.489, 95%
CI: 0.336–0.710,
P<. 0001
30.9 versus nr
HR: 1.638, 95%
CI 0.749–3.582,
P = .211
Maemondo
et al. (2010)
[60]
NEJ002 1st line, EGFR
mutated 230
Geﬁtinib versus
Carboplatin +
Paclitaxel
73.7 versus
30.7
(P<. 001)
10.8 versus 5.4
HR 0.30, 95%
CI: 0.22–0.41,
P<. 001
30.5 versus 23.6
P = .31
R R :r e s p o n s er a t e ;P F S :p r o g r e s s i o n - f r e es u r v i v a l ;O S :o v e r a l ls u r v i v a l ;n r :n o tr e a c h e d .
also demonstrated the superiority of geﬁtinib compared
to carboplatin and paclitaxel in terms of progression-free
survival in intention-to-treat analysis (HR 0.74, 95% CI:
0.65–0.85, P = .001). Because of the crossing of the curves,
the median progression-free survival is similar with both
treatments: however, the pattern of progression-free rates
favors chemotherapy for the ﬁrst 6 months and geﬁtinib
for the remaining 16 months. The initial superiority of
chemotherapy was attributed to the beneﬁt that the EGFR-
mutation-negative subgroup received from chemotherapy
but not from geﬁtinib, whereas prolonged progression-free
survival in the EGFR-mutation-positive subgroup explained
the subsequent improvement favoring geﬁtinib. Crossing of
the curves did not occur in the mutation-positive subgroup
or the mutation-negative subgroup. Another important
ﬁnding of this study was the signiﬁcant interaction between
treatment eﬃcacy and EGFR mutational status. In the sub-
group of patients with EGFR mutation (261 of 437 available
samples), progression-free survival was signiﬁcantly longer
(HR0.48;95%CI0.36–0.64,P = .001),andtheresponserate
was signiﬁcantly higher with geﬁtinib than with carboplatin-
paclitaxel (71.2% versus 47.3%, P = .001). On the contrary,
inthe mutation-negative subgroup,progression-free survival
was signiﬁcantly shorter (HR 2.85; 95%CI 2.05–3.98, P<
.001) and response rate was signiﬁcantly lower with geﬁtinib
(23.5% versus 1.1%, P = .001). Overall survival data were
immature, based on only 37.0% of events, and showed
a similar overall survival between the two groups: 18.6
months with geﬁtinib and 17.3 months with carboplatin-
paclitaxel (HR for death in the geﬁtinib group, 0.91; 95%
CI, 0.76 to 1.10). Final overall survival data conﬁrmed
no diﬀerence between geﬁtinib and chemotherapy, in the
whole population (18.8 months with geﬁtinib versus 17.4
months with chemotherapy, HR 0.90, 95%CI: 0.79–1.02,
P = .11) and in the mutation positive subgroup (HR
1.00, 95%CI: 0.76–1.33) [61]. Patients in the geﬁtinib group
had a clinically relevant improvement in quality of life, as
assessed by FACT-L questionnaire (OR 1.34; 95% CI 1.06–
1.69, P = .01) and by TOI (Trial Outcome Index) scores
(OR 1.78; 95%CI 1.40–2.26; P<. 001). Moreover, geﬁtinib
was associated with a lower rate of grade 3 or 4 adverse
events compared to chemotherapy. The incidences of rash
or acne, diarrhea, and elevated aminotransferase levels were
signiﬁcantlyhigherwithgeﬁtinib,whereas neurotoxiceﬀects,
nausea and vomiting, and hematologic toxic eﬀects were
signiﬁcantly higher with carboplatin-paclitaxel. Interstitial
lung disease events (i.e., the acute respiratory distress
syndrome,interstitiallungdisease,pneumonitis,orradiation
pneumonitis) occurred in 16 patients treated with geﬁtinib
(2.6%) and in 8 patients treated with chemotherapy (1.4%).
A second randomized phase 3 clinical trial compared
geﬁtinib (250mg daily) with cisplatin-gemcitabine as a ﬁrst-
line treatment in 309 Asian, never smokers patients, with
advanced adenocarcinoma [58]. The study failed to reach its
primary endpoint, overall survival, even if geﬁtinib allowed
the achievement of a favorable response rate: 53.5% forJournal of Biomedicine and Biotechnology 9
geﬁtinib versus 45.3% for chemotherapy (OR 1.385, 95%
CI 0.885–2.167, P = .153). The overall mutation rate in
this study was 43.8%: in mutation positive patients, the
response rate was 84.6% for geﬁtinib versus 37.5% for
chemotherapy (P = .002), while, in mutation negative
subgroup, the response rate was 29.9% for geﬁtinib versus
51.9% for chemotherapy (P = .051). Median overall
survival and progression-free survival were similar between
the two groups. There was some diﬀerence in progression-
free survival favoring geﬁtinib in mutation positive patients
(8.5 versus 6.7 months; HR 0.613, 95%CI 0.308–1.221,
P = .0849). There was no diﬀerence in overall survival
by mutation status, both in the overall and EGFR-mutated
populations: it could be due to the poststudy use of EGFR
TKIs in 80.7% of chemotherapy arm.
Two randomized phase 3 studies have been performed
in Japanese, EGFR-mutated patients with advanced NSCLC,
to compare the eﬃcacy of geﬁtinib versus chemotherapy in
the ﬁrst-line setting. In the open label phase III WJTOG3405
trial, 172 EGFR mutated patients were randomly assigned to
receive geﬁtinib (250mg daily) or chemotherapy (cisplatin
80mg/m2 plus docetaxel 60mg/m2 adminstered every 21
days for three to six cycles) [59]. The primary endpoint
was progression-free survival. The study met its endpoint,
showing a median progression-free survival of 9.2 months in
the geﬁtinib group versus 6.3 months in the chemotherapy
group (HR 0.489, 95% CI: 0.336–0.710, P = .0001).
In this molecularly selected population, progression-free
survival curves did not cross, unlike IPASS trial, being the
beneﬁt of geﬁtinib over chemotherapy consistent at any
time of treatment. Response rate was 62.1% and 32.2%
with geﬁtinib and chemotherapy, respectively (P<. 0001).
Myelosuppression, alopecia and fatigue were more frequent
in the cisplatin-docetaxel group, while skin toxicity, liver
dysfunction, and diarrhea in the geﬁtinib group.
Another prospective phase III study, the NEJ002 Trial,
compared geﬁtinib to chemotherapy with carboplatin and
paclitaxel as a ﬁrst-line treatment in advanced NSCLC
patients selected for EGFR mutation [60]. The study was
stopped by independent data and safety monitoring com-
mittee after the preplanned interim analysis, conducted 4
months after the 200th patient enrolled, because it showed
as i g n i ﬁ c a n td i ﬀerence in progression-free survival between
the two treatment groups. The median progression-free
survival was 10.4 months versus 5.5 months for geﬁtinib
andchemotherapy,respectively(HR0.36,95%CI:0.25–0.51,
P<. 001), and the ﬁnal analysis conﬁrmed these results,
showing a median PFS of10.8 versus5.4 months for geﬁtinib
and chemotherapy, respectively (HR 0.30, 95%CI 0.22–0.41,
P<. 001). The response rate was signiﬁcantly higher in
the geﬁtinib than chemotherapy arm (73.7% versus 30.7%,
P<. 001). The median progression-free survival and overall
survival did not diﬀer signiﬁcantly between patients with
exon 19 deletion and those with L858R point mutation(11.5
months versus 10.8 months, resp.). The overall survival did
not diﬀer signiﬁcantly between the two treatment groups
(median survival time and the 2-year survival rate were 30.5
monthsand 61.4% forgeﬁtinibgroup ascompared with 23.6
months and 46.7% for the chemotherapy, resp., P = .31).
Importantly, among 112 patients who had completed ﬁrst-
line carboplatin-paclitaxel, 106 (94.6%) received second-line
geﬁtinib and 58.5% of these patients had a response. The
most common adverse events in the geﬁtinib group were
rash and elevated levels of aspartate aminotransferase or
alanine aminotransferase and, in the chemotherapy arm,
appetite loss, neutropenia, anemia, and sensory neuropathy.
Interstitial lung disease was reported in 6 patients (5.3%)
in the geﬁtinib arm, with one of these fatal. In general,
the incidence of severe toxic eﬀects (NCI-CTC ≥ 3) was
signiﬁcantly higher in the chemotherapy group than in the
geﬁtinib group (71.7% versus 41.2%, P<. 001).
Therefore, these both studies conﬁrmed geﬁtinib to be
superior to chemotherapy in terms of response rate and
progression-free survival in patients with EGFR mutations.
5.Ongoing Phase III/IV Studiesin NSCLC
Several phase III/IV studies are currently ongoing with
geﬁtinib in NSCLC in diﬀerent clinical settings (Table 5).
A double-blind, multicenter, randomized, placebo-
controlled phase III study is evaluating the eﬃcacy, safety,
and tolerability of geﬁtinib as a maintenance therapy in
296 patients with locally advanced or metastatic NSCLC
(INFORM trial, ClinicalTrials.gov ID: NCT00770588).
Patients must have completed 4 cycles of platinum-based
ﬁrst-line doublet chemotherapy without experiencing dis-
ease progression or unacceptable toxicity and are random-
ized to geﬁtinib or placebo at 1:1 ratio. The primary
endpoint is progression-free survival; secondary endpoints
are overall survival, objective tumor response, quality of life,
and safety proﬁle in terms of adverse events.
Another randomized phase III trial is evaluating the
eﬃcacy of a maintenance therapy with geﬁtinib compared
with placebo in 600 Japanese patients treated with ﬁrst-line
chemotherapy forstage IIIBorIVNSCLC(ClinicalTrials.gov
ID:NCT00144066).Theprimary aimofthestudyistodeter-
mine if geﬁtinib improves overallsurvival of thepatients that
did not progress on prior ﬁrst line induction chemotherapy.
Secondary objectives are progression-free survival and safety
proﬁle.
A phase IV study is investigating the activity and
safety of geﬁtinib as ﬁrst-line therapy for 100 Caucasian
patients with EGFR-positive mutations (ClinicalTrials.gov
ID: NCT01203917). The primary endpoint is the objective
response rate; secondary endpoints are disease control rate,
safety data, and overall survival.
A randomized phase III clinical study will compare geﬁ-
tinib versus pemetrexed in never-smoker patients with ade-
nocarcinoma histotype, previously treated with platinum-
based chemotherapy (ClinicalTrials.gov ID: NCT01066195).
The estimated enrollment is of 129 patients, and the main
endpoints are progression-free survival, overall survival,
objective response rate, and toxicity.
A randomized, open label, phase III study is enrolling
226 East Asian never or light ex-smoker patients with locally
advanced or metastatic nonsquamous NSCLC, with the aim
to compare ﬁrst line cisplatin + pemetrexed for 6 cycles10 Journal of Biomedicine and Biotechnology
Table 5: Ongoing phase III/IV studies in NSCLC.
Study
phase
Line of
treatment
ClinicalTrials.gov
ID Setting
Estimated
sample
size (pts)
Treatment Primary
endpoint
III 1st NCT00770588
Maintenance after ﬁrst
line platinum-based
chemotherapy
296 Geﬁtinib 250mg versus
Placebo
Progression-free
survival
III 1st NCT00144066
Maintenance after ﬁrst
line platinum-based
chemotherapy
600 Geﬁtinib 250mg versus
Placebo Overall survival
IV 1st NCT01203917 Selected Caucasian pts 100 Geﬁtinib 250mg Objective
response rate
III ≥2nd NCT01066195 Never smoker pts with
adenocarcinoma 129 Geﬁtinib 250mg versus
Pemetrexed
Progression-free
survival
III 1st NCT01017874 Selected East Asian pts 226
Geﬁtinib alone versus
Cisplatin-
Pemetrexed→Geﬁtinib
Progression-free
survival
IV 1st NCT00173524 First line Asian pts 200
Geﬁtinib versus
Platinum-based
chemotherapy
Cost-
eﬀectiveness
Systemic and radiant
III 1st-2nd NCT00955695
Never smoker
adenocarcinoma pts
treated with
prophylactic cranial
irradiation
242
Prophylactic whole brain
radiation therapy during
geﬁtinib 250mg or
erlotinib 150mg
Incidence of
symptomatic
brain metastases
followed by geﬁtinib for 6 courses (each of 21 days)
versus geﬁtinib alone for 6 courses (each of 21 days)
(ClinicalTrials.gov ID: NCT01017874). Primary endpoint is
progression-free survival; secondary endpoints are overall
survival, tumor response rate, disease control rate, time to
progression, duration of response, and time to worsening of
health-related quality of life. The trial should be completed
in 2013.
Amulticenterrandomized phase IIIstudy isinvestigating
the eﬃcacy of whole brain radiation therapy compared
with observation in preventing brain metastases in 242
patients with advanced NSCLC responding to ﬁrst- or
second-line geﬁtinib (250mg/day) or erlotinib (150mg/day)
administered continuatively until disease progression or
unacceptabletoxicity (ClinicalTrials.gov ID: NCT00955695).
Patients must be never smoker, with a diagnosis of ade-
nocarcinoma with the EGFR-positive mutations on exon
19 or 21. Prophylactic cranial irradiation consists of 25Gy
cumulative dose over 10 fractions. The primary end-
point is the incidence of symptomatic brain metastases.
Secondary endpoints are overall survival, progression-free
survival, safety, psycho-neurological eﬀects, and quality of
life.
A phase IV pharmacoeconomics study will have the
objective to analyze the cost-eﬀectiveness and the cost-utility
of geﬁtinib as a ﬁrst-line treatment for 200 patients aﬀected
by stage IIIB or IV NSCLC, compared with the conventional
ﬁrst-line platinum-based chemotherapy (ClinicalTrials.gov
ID: NCT00173524).
6.Discussionand Conclusions
The developmentof geﬁtinib in NSCLC is a clear example of
the diﬃculties in designing and conducting of clinical trials
with new molecular-targeted agents and of the uncertainty
about predictive factors and selection criteria [62]. Crucial
points, regarding the methodology of clinical research with
target-based agents, especially for phase 3 trials, are how
should patients be selected and which patients are expected
to beneﬁt from a targeted agent [63]. The proper character-
ization of a molecular target that allows the identiﬁcation of
responding versus nonresponding patients to a molecular-
targeted agent could have important implications for the
design of randomized trials evaluating the eﬃcacy of the
drug. In fact, the presence of unrecognized molecular
heterogeneity can result in a falsely negative study that could
be underpowered and may fail to detect a truly eﬀective new
therapy, leading to the rejection of a potentially useful drug
[64].
Geﬁtinib was the ﬁrst targeted drug that entered into
clinical practice for the treatment of lung cancer: however,
the positive results obtained in early clinical trials were not
conﬁrmed in large phase 3 trials, testing the eﬃcacy of
geﬁtinib in unselected patients with advanced NSCLC and,
therefore, the use of geﬁtinib in clinical practice was stopped
for several years.
It has been then shown that the presence of somatic
mutations in the kinase domain of EGFR strongly correlates
with increased responsiveness to EGFR tyrosine kinaseJournal of Biomedicine and Biotechnology 11
inhibitors in patients with advanced NSCLC and that a
substantial percentage of tumors with objective response
to geﬁtinib or erlotinib harbours somatic mutations in the
EGFR gene [42, 43, 65]. Moreover, clinical and demographic
factors, including female sex, nonsmoking status, adenocar-
cinoma histotype, and Asian race have been identiﬁed as
potentially predictive of the eﬃcacy of EGFR tyrosine kinase
inhibitors.
Currently, 4 randomized clinical trials have demon-
strated the eﬃcacy of geﬁtinib as a ﬁrst-line treatment of
NSCLC patients harbouring EGFR mutations: the IPASS
and the First-SIGNAL studies, conducted in Asian patients
selected for clinical factors; the WJTOG 3405 and the
NEJ002 studies, conducted in patients selected for the
presence of EGFR-activating mutations [57–60]. All these
trials have demonstrated a statistically signiﬁcant increase
in progression-free survival with geﬁtinib compared to
platinum-based chemotherapy in patients with EGFR-
mutated advanced NSCLC. Moreover, treatment with geﬁ-
tinib was associated with evidence of high objective response
rate, better quality of life and more favourable toxicity
proﬁle. On these bases, in July 2009 geﬁtinib received
from EMEA the authorization for the treatment of locally
advanced or metastatic NSCLC with activating mutations of
EGFR, across all lines of therapy and, currently, it can be
considered the standard ﬁrst-line treatment of patients with
advanced NSCLC harbouring EGFR mutations.
Similar results have beenrecently obtained with erlotinib
in a phase 3 clinical trial conducted in China (the OPTIMAL
trial), comparing erlotinib to gemcitabine plus carboplatin,
in EGFR-mutation-positive tumors in terms of progression-
freesurvival[66].TheOPTIMALstudyshowedthaterlotinib
was signiﬁcantly superior to chemotherapy in terms of
progression-free survival (13.1 versus 4.6 months, HR 0.16,
95%CI: 0.10–0.26, P<. 0001) and also in terms of objective
response rate (83% versus 36%).
On the contrary, a treatment strategy based on a tyrosine
kinase inhibitor (erlotinib) as a ﬁrst-line therapy, followed
at progression by chemotherapy in unselected patients with
advanced NSCLC, is inferior to standard treatment with a
ﬁrst-line platinum-based doublet,followed at progression by
erlotinib and cannot be recommended in clinical practice
[67].
Several questions need to be addressed, regarding the
reproducibility of these results in Western patients with
NSCLC and EGFR mutations, the proper tyrosine kinase
selection (geﬁtinib versus erlotinib), the lack of a survival
beneﬁt with ﬁrst-line geﬁtinib in all these studies, the most
appropriate clinical use of TKIs in mutated patients (ﬁrst
versus second line), the eﬃcacy of geﬁtinib as neoadjuvant
therapyorincombinationwithradiotherapyinpatientswith
locally advanced NSCLC and EGFR mutations, and over-
coming resistance to tyrosine kinase inhibitors. A large ran-
domized phase 3 trial (the EURTAC trial, ClinicalTrial.gov
ID NCT00446225) testing erlotinib in Western patients
harbouring EGFR mutation is addressing the ﬁrst question.
Conversely, there are no ongoing phase 3 trials that directly
compare geﬁtinib with erlotinib: therefore, the choice of the
tyrosine kinase inhibitor to use in clinical practice should
be based on evidence coming from these randomized trials.
Whether progression-free survival prolongation translates
intosurvivalgain isnotyetclear:maturedatafromtheIPASS
t r i a ls h o w e dn os u r v i v a ld i ﬀerence between ﬁrst-line geﬁ-
tinib and chemotherapy, probably due to treatment cross-
over of patients with tumor harbouring EGFR mutation
[61].
The lack of a survival beneﬁt with ﬁrst-line geﬁtinib
raises the question regarding its use as ﬁrst- or second-
line therapy, in patients selected by the presence of EGFR
mutation. Data from Western and Asian patients suggest
that there was no statistically signiﬁcant diﬀerence in overall
survival between patients receiving EGFR inhibitors as a
ﬁrst-line therapy or after failure of previous chemotherapy
[68, 69]. However, these analyses were not based on a
prospective comparison between the two strategies (ﬁrst-
versus the second-line therapy with EGFR inhibitors).
Moreover, it should be considered that, for patients who
do not receive ﬁrst-line tyrosine kinase inhibitors, there
is the risk of never receiving an EGFR inhibitor at the
time of disease progression, due to a rapid worsening of
clinical conditions. Finally, the better qualityof life and more
favourable toxicity proﬁle with ﬁrst line geﬁtinib, in addition
to the prolonged progression-free survival, compared to
chemotherapy, strongly support the use of geﬁtinib as a ﬁrst-
line therapy in patients with activating EGFR mutations.
The ﬁnal results of ongoing clinical trials should deﬁne
the eﬃcacy of geﬁtinib also as neoadjuvant therapy or
in combination with radiotherapy in patients with locally
advanced NSCLC and EGFR mutations, while the develop-
ment of irreversible inhibitors of EGFR tyrosine kinases [70]
may have the potential to overcome the resistance to tyrosine
kinase inhibitors.
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